To assess the potential clinical relevance of these miRNAs that targeted COUP-TFII to impact metastatic PCa, we used an in silico approach to systematically analyse the changes in levels of miRNAs in metastatic PCa employing two different public miRNA data sets (GSE21036 and GSE26964) and used a criteria of false discovery rate (FDR) <0.05 and more than twofold change. The gene discussed is NR2F2; the disease is posterior cortical atrophy.